Stockscreener 앱 받기
9.82
4.25%
0.40
시간 외 거래:
9.87
0.05
+0.51%
전일 마감가:
$9.42
열려 있는:
$9.46
하루 거래량:
1.17M
Relative Volume:
1.71
시가총액:
$612.93M
수익:
-
순이익/손실:
$-106.81M
주가수익비율:
-4.4636
EPS:
-2.2
순현금흐름:
$-8.40M
1주 성능:
-0.86%
1개월 성능:
-16.14%
6개월 성능:
-31.90%
1년 성능:
+23.68%
1일 변동 폭
$9.325
$10.03
1주일 범위
$8.97
$10.20
52주 변동 폭
$6.93
$30.96
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IMNM | 9.82 | 612.93M | 0 | -106.81M | -8.40M | -2.20 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Immunome files to sell 1.8M shares of common stock for holders - TipRanks
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Victory Capital Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks
Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks
Immunome Inc (IMNM) Q3 2024 Earnings: Revenue Surpasses Estimates at $2.91M, GAAP EPS Misses at -$0.78 - GuruFocus.com
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunome Reports $47.1M Q3 Loss, Advances Cancer Pipeline with Strong Cash Position | IMNM Stock News - StockTitan
(IMNM) Technical Pivots with Risk Controls - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Gap Up – Still a Buy? - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Analyst Expectations For Immunome's Future - Benzinga
Immunome (NASDAQ:IMNM) Shares Gap UpTime to Buy? - MarketBeat
Immunome (NASDAQ:IMNM) Now Covered by Stephens - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC - Defense World
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - The Bakersfield Californian
Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com
Immunome (NASDAQ:IMNM) Trading Up 8.7%Time to Buy? - MarketBeat
Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World
Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat
Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN
Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily
Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex
Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):